At a glance
ClinicalIndex Comparison RecordN/ACompleted· 628 enrolled
Drug / intervention
Aspirin 100mg +2 moredrug
Likely dose
Aspirin 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Antiplatelet Removal and HemocompatIbility EventS With the HeartMate 3 Pump IDE Study
In Brief
A clinical study evaluating LVAD Implant, Aspirin 100mg, and 1 other intervention for Heart Failure. Completed, enrolled 628 participants across 51 sites in 9 countries.
Detailed Summary
Prospective, randomized, double-blinded, placebo-controlled clinical investigation of advanced heart failure patients treated with the HM3 with two different antithrombotic regimens: vitamin K antagonist with aspirin versus vitamin K antagonist with placebo
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesAustralia, Austria, Canada, Czechia, France, Italy, Kazakhstan, United Kingdom, United States
Collaborators--
Timeline
N/ACompletedFinished
2020202120222023202420252026
First PostedAug 2019
Enrollment StartJul 2020
Primary CompletionAug 2023
TodayJul 2026
First PostedAug 28, 2019
Enrollment StartJul 14, 2020
Primary CompletionAug 10, 2023
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 6.8 years ago
Interventions
LVAD Implantdevice
Subjects will undergo Heartmate 3 LVAD implant prior to randomization
Aspirin 100mgdrug
Subjects will be randomized to either Placebo or Aspirin post implant.
Placebo oral tabletdrug
Subjects will be randomized to either Placebo or Aspirin post implant